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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
Coronary artery disease in women: a review
on prevention, pathophysiology, diagnosis, and
treatment
A
u
t
h
o
r
 
c
o
p
y
 
o
n
l
y
© 2007 Dove Medical Press Limited.   All rights reserved
Vascular Health and Risk Management 2007:3(5) 691–700 691
REVIEW
Utilizing enoxaparin in the management of STEMI
Andrea Rubboli1
Alessandro Capecchi2
Giuseppe Di Pasquale1
1Division of Cardiology, Maggiore 
Hospital, Bologna, Italy; 2Division 
of Cardiology, General Hospital, 
Bentivoglio, Italy
Correspondence: Andrea Rubboli
Cardiac Catheterization Laboratory, 
Division of Cardiology, Maggiore Hospital, 
Largo Nigrisoli 2, 40133 Bologna, Italy
Tel +390516478976
Fax +390516478635
Email andrearubboli@libero.it
Abstract: The use of enoxaparin in conjunction with thrombolysis in ST-elevation acute 
myocardial infarction (STEMI), has been recently investigated in several clinical trials. 
In 8 published open-label studies including about 10,000 patients, in which enoxaparin was 
compared to either placebo or unfractionated heparin (UFH), a general superiority of enoxaparin 
on both reinfarction/recurrent angina and patency of the infarct-related artery, was observed. 
Overall, bleeding rate with enoxaparin was higher than with placebo and comparable to UFH, 
with the exception of one study where pre-hospital administration induced a doubled incidence 
of intracranial bleeding in patients older than 75 years. In a recent double-blind, randomized, 
mega-trial including over 20,000 patients, the superior efﬁ  cacy on in-hospital and 30-day 
adverse cardiac events (namely reinfarction), and comparable safety on intracranial bleedings 
of enoxaparin compared to UFH, was deﬁ  nitively proven.
In conclusion, initial intravenous bolus of enoxaparin followed by twice daily subcutane-
ous administration for about 1 week should be considered instead of intravenous UFH for the 
treatment of patients with STEMI receiving thrombolysis. Along with its easiness of use, not 
requiring laboratory monitoring, the subcutaneous administration of enoxaparin allows extended 
antithrombotic treatment, while permitting early mobilization (and rehabilitation) of patients.
Keywords: enoxaparin, low-molecular-weight heparins, thrombolysis, acute myocardial 
infarction
Introduction
In patients with ST-elevation acute myocardial infarction (STEMI) undergoing 
thrombolytic treatment with ﬁ  brin-speciﬁ  c agents (such as alteplase, reteplase, and 
tenecteplase), concurrent anticoagulation is warranted, in order to improve early 
recanalization and reduce reocclusion and reinfarction rates (Van de Werf et al 2003; 
Antman et al 2004). The need for systemic anticoagulation is less compelling when non-
speciﬁ  c agents (such as streptokinase, anistreplase or urokinase) are used, since they 
produce a profound and prolonged systemic coagulopathy, which make these agents 
acting as anticoagulants themselves (Van de Werf et al 2003; Antman et al 2004). In 
the setting of STEMI treated with thrombolysis, conjunctive systemic anticoagulation 
has been traditionally carried out by means of a 24–48 hours intravenous course of 
unfractionated heparin (UFH) (Van de Werf et al 2003; Antman et al 2004). However, 
the efﬁ  cacy of such treatment is known to be suboptimal, probably due to the several 
pharmacokinetic (ie, binding to plasma proteins with consequent variable anticoagulant 
response) and biophysical (ie, inability to inactivate factor Xa in the prothrombinase 
complex and thrombin bound to ﬁ  brin) limitations of UFH (Hirsh et al 2001).
The low-molecular-weight heparin enoxaparin is potentially more effective 
than UFH because of its pharmacological peculiarities. The anticoagulant effect of 
enoxaparin in fact, is exerted mainly by inactivating factor Xa, therefore inducing a 
more proximal inhibition of the coagulation cascade which in turn, results in a ratio 
of anti-factor Xa to anti-factor IIa activity of 3.8:1 (Antman 2001). In addition, the 
absence of a signiﬁ  cant binding to plasma proteins and platelet factors increases the Vascular Health and Risk Management 2006:2(4) 465–475
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1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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bioavailability and plasma half-life of enoxaparin, therefore 
rendering the dose-response relationship more predictable 
(as opposed to UFH which shows wide ﬂ  uctuations of its 
anticoagulant effect), with consequent no need for therapeutic 
monitoring (Antman 2001; Hirsh et al 2001).
Enoxaparin has been extensively investigated in non 
ST-elevation acute coronary syndromes, where it was 
proven at least as effective as intravenous UFH (Cohen et al 
1997; Antman et al 1999). Whereas either intravenous UFH 
administration or subcutaneous enoxaparin administration 
is the anticoagulation treatment currently recommended for 
the management of patients with non ST-elevation acute 
coronary syndromes (Bertrand et al 2002; Braunwald et al 
2002), the current standard of treatment after thrombolysis in 
STEMI is represented by intravenous UFH, being subcutane-
ous enoxaparin only regarded as an acceptable alternative 
(Antman et al 2004).
Until very recently in fact, the evidence on the efﬁ  cacy and 
safety of enoxaparin in this setting was derived from few open-
label studies, generally including relatively small populations 
(Glick et al 1996; ASSENT 2001; Ross et al 2001; Antman et al 
2002; Baird et al 2002; Simoons et al 2002; Wallentin et al 2003; 
Tatu-Chitoiu et al 2004). In 2006, the results of a double-blind, 
randomized, mega-trial comparing the effect of enoxaparin with 
that of UFH in over 20,000 patients undergoing thrombolysis for 
STEMI were published, therefore clarifying the role of enoxa-
parin in this clinical setting (Antman et al 2006).
Overview and analysis
of the open-label clinical studies
In 8 open-label published studies, enoxaparin was evalu-
ated in about 10,000 patients (Table 1). In these studies, the 
efﬁ  cacy and safety of enoxaparin, in conjunction with either 
ﬁ  brin-speciﬁ  c (ASSENT 2001; Ross et al 2001; Antman 
et al 2002; Wallentin et al 2003; Tatu-Chitoiu et al 2004), 
non ﬁ  brin-speciﬁ  c (Glick et al 1996; Simoons et al 2002) or 
either one (Baird et al 2002) of the thrombolytic agents, was 
compared with either placebo (Glick et al 1996; Simoons et al 
2002) or UFH (ASSENT 2001; Ross et al 2001; Antman et al 
2002; Baird et al 2002; Wallentin et al 2003; Tatu-Chitoiu 
et al 2004) (Table 1).
Enoxaparin versus placebo (Tables 1 and 2)
Glick et al (1996) randomized 103 patients to either subcu-
taneous enoxaparin 4,000 IU/day or placebo for the next 25 
days, following treatment with aspirin, streptokinase and 
UFH for 5 days. The primary end-point of combined occur-
rence of unstable angina, reinfarction and death at 6 months 
was signiﬁ  cantly reduced in the enoxaparin group (14% vs 
43%; p = 0.01), mainly as a consequence of the decreased 
reinfarction rate (5% vs 22%; p = 0.02), since the occurrence 
of unstable angina (9% vs 22%) and death (0% vs 2%) were 
comparable.
In the AMI-SK study (Simoons et al 2002), 496 patients 
treated with aspirin and streptokinase were randomized to 
enoxaparin (30 mg intravenous bolus followed by 1 mg/kg 
twice daily subcutaneously for 3–8 days) or placebo. The 
primary end-point was the infarct-related artery (IRA) 
patency rate at 5–10 days, while secondary end-points were 
ST-segment resolution at 90' and 180' and occurrence of com-
bined death, reinfarction, recurrent angina and major bleed-
ings at 30 days. Enoxaparin was signiﬁ  cantly more effective 
on the primary end-point (TIMI 3 ﬂ  ow grade 70% vs 58%; 
p = 0.01 and TIMI 2–3 ﬂ  ow grade 88% vs 72%; p = 0.001) 
and complete ST-segment resolution both at 90' (16% vs 11%; 
p = 0.01) and 180’ (36% vs 25%; p = 0.004). Clinical events 
at 30 days were also signiﬁ  cantly reduced in the enoxaparin 
group (13% vs 21%; p = 0.03), mainly as a consequence of the 
reduction of reinfarction (2% vs 7%; p = 0.01), whereas major 
haemorrhages were more frequent, although this difference 
was not statistically signiﬁ  cant (5% vs 3%).
Enoxaparin versus UFH (Tables 1 and 2)
In the HART-II study (Ross et al 2001), 400 patients receiv-
ing aspirin and accelerated rt-PA, were randomized to 
intravenous bolus of enoxaparin 30 mg followed by 1 mg/kg 
subcutaneously twice daily or intravenous bolus of UFH 
5.000 IU followed by 15 IU/kg/h for at least 3 days. The 
primary end-point was the IRA patency at 90' and 5–7 days, 
while the secondary end-point was the occurrence of major 
bleedings. At 90’ TIMI 2–3 (80% vs 75%) and TIMI 3 (53% 
vs 48%) ﬂ  ow grades in the IRA did not signiﬁ  cantly differ 
in the two groups. Also, the reocclusion rate at 5–7 days was 
comparable, although a clear trend favoring enoxaparin was 
evident (3% vs 9%). Major bleedings occurred with similar 
frequency in both groups (5.6% vs 5%).
In the ASSENT-3 trial (ASSENT 2001), 6095 patients 
treated with aspirin were randomized to: 1) full-dose 
tenecteplase and enoxaparin (30 mg intravenous bolus 
followed by 1 mg/kg to be repeated every 12 h up to 
hospital discharge or revascularization, for a maximum 
of 7 days); 2) half-dose tenecteplase with weight-adjusted 
low-dose UFH (40 IU/kg bolus followed by 7 IU/kg) and 
a 12-h infusion of abciximab; 3) full-dose tenecteplase 
and weight-adjusted UFH (60 IU/kg bolus followed by 12 
IU/kg/h) for 48 h. Primary end-points were the composites Vascular Health and Risk Management 2006:2(4) 465–475
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most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
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alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
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of 30-day mortality, in-hospital reinfarction/refractory 
ischemia (efficacy end-point), and the above end-points 
plus in-hospital intracranial hemorrhage/major bleed-
ings (efficacy plus safety end-point). In association with 
full-dose tenecteplase, enoxaparin was significantly more 
effective on the primary efficacy end-point (11% vs 15%; 
p = 0.0001), as well as on the primary efficacy plus safety 
end-point (14% vs 17%; p = 0.004). The association of 
abciximab and UFH influenced both efficacy and efficacy 
plus safety end-points comparably to enoxaparin and 
superiorly to UFH. Enoxaparin significantly reduced in-
hospital reinfarction (3% vs 4%; p = 0.02) and refractory 
ischemia (5% vs 7%; p < 0.0001), along with in-hospital 
death/reinfarction (7% vs 9%; p = 0.02). Major hemor-
rhagic complications were not significantly different with 
enoxaparin as compared to UFH (3% vs 2%).
The ENTIRE-TIMI 23 study (Antman et al 2002) was 
carried out on 483 patients to determine the effect on the 60' 
patency rate of the IRA of 4 pharmacologic regimens, includ-
ing the three evaluated in the ASSENT-3 trial (ASSENT 
2001), plus an additional one with half-dose tenecteplase 
associated with enoxaparin 1 mg/kg every 12 h subcutane-
ously (to be continued up to 8 days) and 12-h intravenous 
abciximab infusion. The 4 regimens were similarly effective 
on the primary end-point of IRA TIMI 3 ﬂ  ow grade at 60', 
which was about 50% in all groups. When pooling the results 
of the different groups according to heparin treatment, the 
TIMI 3 (50% vs 51%) and TIMI 2–3 (75% vs 78%) ﬂ  ow 
grade rates were comparable. A favorable trend towards a 
complete ST-segment resolution at 180’ was observed in 
enoxaparin groups (pooled rate: 50% vs 43%). Evaluation 
at 30 days by a blinded Clinical Events Committee of the 
Table 1 Design of the Studies
  No of  General treatment   Active treatment  Control  Treatment
 patients        duration
Enoxaparin versus placebo
Glick et al (1996)  103  SK + ASA + UFH iv  E 40 mg/die sc  placebo  25 days
Simoons et al (2002)  496  SK + ASA  E 30 mg iv +  placebo  3–8 days
(AMI-SK)      E 1 mg/kg sc × 2
Enoxaparin versus UFH
Ross et al (2001)  400  rt-PA + ASA  E 30 mg iv +  UFH 5.000 IU iv  3 days
(HART-II)      E 1mg/kg sc × 2  + 15 IU/kg/h iv 
ASSENT-3 (2001)  6095  –  – full-dose TNK + ASA +  –  7 days E/48 h UFH
      E 30mg iv + 1 mg/kg sc × 2
      – full-dose TNK + ASA +  –
      UFH 60 IU/kg iv +12 IU/kg/h iv
      – half-dose TNK + ASA +  –
       UFH 40 IU/kg +7 IU/kg iv + 
      abciximab 12 h 
Antman et al (2002)  483  –  as in ASSENT–3 trial +    8 days E/ 36 h UFH
(ENTIRE-TIMI 23)      – half-dose TNK + ASA +
      E 1 mg/kg sc × 2 +
      abciximab 12 h
Baird et al (2002)  300  Thrombolytic  E 40 mg iv + 40 mg sc × 3  UFH 5.000 IU iv  4 days
        + 30.000 IU iv 24 h
Wallentin et al (2003)  1639  TNK + ASA   E 30 mg iv +  UFH 60 IU/kg  7 days E/48 h UFH
(ASSENT-3 PLUS)      E 1 mg/kg sc × 2  + 12 IU/kg/h iv
Tatu-Chitoiu et al  429  ASK + ASA +  E 40 mg iv +  UFH 1.000  7 days E/ 72 h UFH
(2004) (ASENOX)    E 40 mg iv +  E 1 mg/kg sc × 2  IU/h iv
Abbreviations: E, enoxaparin; rt-PA, alteplase; SK, streptokinase; ASK, accelerate regimen of streptokinase in 20 min; TNK, tenecteplase; ASA, aspirin; UFH, unfractionated 
heparin; IRA, infarct-related artery; sc, subcutaneously; iv, intravenously; h, hoursVascular Health and Risk Management 2006:2(4) 465–475
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expected to rise even more during the next decades, due to an increase of diabetes and
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Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
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clinical efﬁ  cacy end-points showed signiﬁ  cantly less death/
reinfarction (4% vs 16%; p = 0.005) with enoxaparin, when 
administered with full-dose tenecteplase. This was mainly 
due to the reduction in reinfarction (2% vs 12%; p = 0.003), 
which could also be observed when pooling all enoxaparin 
vs all UFH patients (5% vs 11%; p = 0.01). No effect of 
the two heparin regimens was apparent with the combina-
tion treatments including abciximab. Through 30 days, the 
occurrence of major bleedings was similar (about 2%) in 
both groups treated with full-dose tenecteplase, regardless 
of the heparin regimen used. When abiciximab was added, 
a trend towards a higher bleeding rate was observed with 
enoxaparin as compared to UFH (9% vs 5%). Such a trend 
was also apparent for enoxaparin when pooling patients with 
respect to the heparin regimen adopted (5% vs 4%).
Baird et al (2002) enrolled 300 patients receiving strepto-
kinase or anistreplase (but not aspirin, which was given only 
at the end of the investigated treatment), who were random-
ized to a 4-day regimen with either enoxaparin 4.000 IU 
intravenous bolus followed by 4.000 IU three times daily 
subcutaneously or UFH intravenous 5.000 IU bolus followed 
by 30.000 IU/day infusion. The primary end-point was the 
occurrence at 90 days of the composite of death, reinfarc-
tion or rehospitalization due to unstable angina. Enoxaparin 
was signiﬁ  cantly more effective than UFH (26% vs 36%; 
p = 0.04), leading to a 30% relative risk reduction of death, 
reinfarction or recurrent angina. This effect was obtained 
through a consensual reduction of any single component 
of the composite end-point. Signiﬁ  cant bleeding occurred 
comparably in the two treatment groups (3% vs 4%).
In the ASSENT-3 PLUS study (Wallentin et al 2003), 
1,639 patients were randomly assigned in a pre-hospital 
setting to treatment with tenecteplase and either enoxaparin 
(30 mg intravenous bolus followed by 1 mg/kg subcutane-
ously twice daily for a maximum of 7 days) or weight-
adjusted UFH (60 IU/kg intravenous bolus followed by 12 
IU/kg infusion) for 48 hours. The primary end points were: 
composite of 30-day mortality or in-hospital reinfarction/
Table 2 Results of the studies
 End  points  Active  Control  p
   treatment
Enoxaparin versus placebo
Glick et al (1996)  1°: death, reinfarction, angina at 6 months  14%  43%  <0.05
Simoons et al (2002) (AMI-SK)  1°: TIMI 3 grade ﬂ  ow at 5–10 days  70%  58%  <0.05
 2 °: death, reinfarction, angina at 30 days  13%  21%  <0.05
 2 °: major bleeding at 30 days  5%  3%  NS 
Enoxaparin versus UFH
Ross et al (2001) (HART-II)  1°: TIMI 2–3 grade ﬂ  ow in IRA at 90'  80%  75%  NS
 2 °: in-hospital major bleedings  5.6%  5%  NS
ASSENT-3 (2001)  1°: death at 30 days, in-hospital reinfarction/angina  11%  15%  <0.05
 1 °: previous + in-hospital major bleedings  14%  17%  <0.05
 2 °: in-hospital reinfarction/refractory ischemia  3/5 %   4/7%   <0.05
 2 °: in-hospital major bleendigs  3%  2%   NS
Antman et al (2002) (ENTIRE-TIMI 23)   1°: TIMI grade 3 ﬂ  ow at 60'  50%  51%   NS
 1 °: major bleedings at 30 days  2%  2%  NS
 2 °: death, reinfarction at 30 days  4%  16%  <0.05
Baird et al (2002)  1°: death, reinfarction, angina at 90 days  26%  36%  <0.05
 2 °: major bleeding at 4 days  3%  4%  NS
Wallentin et al (2003) (ASSENT-3 PLUS)  1°: death at 30 days, in-hospital reinfarction/angina   14%  17%  NS
 1 °: previous + in-hospital major bleedings  18%  20%   NS
 2 °: stroke + intracranial hemorrhage  2%  1%   NS
Tatu-Chitoiu et al (2004) (ASENOX)  1°: Reperfusion rate (noninvasive criteria)  78%  74%   NS
 2 °: mortality at 30 days  6%  7%   NS
Abbreviations:1°, primary end-point; 2°, secondary end-point; IRA, infarct-related artery.Vascular Health and Risk Management 2006:2(4) 465–475
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those in men. In addition, pathology and pathophysiology of the disease present significant
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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refractory ischemia (efﬁ  cacy end point) and composite of 
the previous plus in-hospital intra-cranial hemorrhage/major 
bleedings (efﬁ  cacy plus safety end point). Enoxaparin was 
comparable to UFH on both the primary efﬁ  cacy (14% vs 
17%) and efﬁ  cacy plus safety (18% vs 20%) end points. 
Analysis of the individual components of the end points 
showed a reduction in in-hospital reinfarction (4% vs 6%; 
p = 0.03) and refractory ischemia (4% vs 7%; p = 0.07) rates, 
but an increase in total stroke (3% vs 2%; p = 0.03) and intra-
cranial hemorrhage (2% vs 1%; p = 0.05) with enoxaparin. 
The increase in intracranial hemorrhage however, was seen 
exclusively in patients over 75 years of age.
The ASENOX study (Tatu-Chitoiu et al 2004) included 
633 consecutive patients who received aspirin and were 
randomly assigned to either: (1) streptokinase 1.500.000 U 
in an accelerated fashion (ie, over 20', either as a full dose 
or double infusion of 750.000 U in 10' separated by 50’), 
plus an intravenous bolus of enoxaparin 40 mg followed by 
1 mg/kg subcutaneously every 12 h for 5–7 days (ASKEnox 
group = 165 patients); (2) the same accelerated streptoki-
nase regimen plus UFH 1,000 IU/h for 48–72 h (ASKUFH 
group = 264 patients); or (3) streptokinase 1.500.000 U over 
60’ plus UFH 1,000 IU/h for 48–72 h (SSKUFH group = 204 
patients). When considering the 429 patients in the ASKEnox 
and ASKUFH groups, the coronary reperfusion rate (deﬁ  ned 
as cessation of chest pain during the ﬁ  rst 180' of thrombolysis, 
rapid reduction of ST-segment elevation by more than 50% 
of the initial value within the ﬁ  rst 180' and rapid increase in 
plasma CK and CK-MB with a peak in the ﬁ  rst 12 h) was 
comparable (78% vs 74%). Also 30-day mortality was com-
parable in both groups (6% vs 7%) and neither signiﬁ  cant 
difference in the incidence of major or minor hemorrhage 
was observed.
A pooled analysis of the studies where major adverse 
cardiac events, such as reinfarction and death, were evalu-
ated in comparison to UFH, shows a consensual favorable 
effect of enoxaparin at both 7 and 30 days, with the only 
exception of ASSENT-3 PLUS (Wallentin et al 2003) 
where a trend towards an increased mortality was observed 
(Tables 1 and 2). Overall, the short- and medium-term 
beneﬁ  cial effect of enoxaparin was statistically signiﬁ  cant 
for the in-hospital/7 days reinfarction rate (RR reduction 
39%), as well as for the 30-day combined occurrence of 
death and reinfarction (RR reduction 30%) (Tables 3 and 4). 
As regards mortality, enoxaparin treatment was associated 
with a favorable, albeit non signiﬁ  cant, effect both during 
hospitalization/at 7 days (RR reduction 11%) and at 30 days 
(RR reduction 2%) (Tables 3 and 4). A similar analysis of 
the pooled data relative to the incidence of major bleedings 
in the studies comparing enoxaparin and UFH, showed a 
favorable, although not statistically signiﬁ  cant, effect of 
enoxaparin during hospitalization/at 7 days (RR reduction 
14%), whereas a trend towards an increase in major hemor-
rhagic complications is apparent at 30 days (RR increase 
76%) (Table 5). However, the limited number of patients 
evaluated and the someway discordant occurrence of major 
bleeding in the individual studies, a trend towards an increase 
being observed in the ASSENT-3 trial (ASSENT 2001), as 
opposed to the ENTIRE-TIMI 23 trial (Antman et al 2002) 
were major bleedings tended to be less, should be acknowl-
edged (Tables 2 and 5).
Comment on the open-label studies
The differences in study designs, end-points evaluated and 
treatment modality and duration (Table 1) make difﬁ  cult an 
analysis of the efﬁ  cacy and safety of enoxaparin as an adjunct 
to thrombolysis in STEMI, both on angiographic and clinical 
end points (Table 2).
In general however, enoxaparin showed a somewhat 
higher efﬁ  cacy than UFH on both early (60–90 minutes) and 
late (5–10 days) patency rates and reocclusion rate of IRA 
(Ross et al 2001; Antman et al 2002) (Table 2). Formal statis-
tical signiﬁ  cance however was never reached, probably due to 
the small size of the population. When compared to placebo, 
as in the AMI-SK study (Simoons et al 2002), enoxaparin 
proved highly effective on the IRA patency rate (TIMI 3 ﬂ  ow 
grade at 8 days: 70% and 58%; p  0.01) (Table 2).
Regarding the clinical end-points, both efﬁ  cacy and 
safety of enoxaparin appear superior, not only to placebo, 
but also to UFH, although the above mentioned differences 
in study designs and results must be kept in mind (Tables 
2–4). When noting that the most important clinical end 
point (ie, mortality) was not signiﬁ  cantly inﬂ  uenced by 
enoxaparin, it should be taken into account that none of 
the studies was neither designed nor sized to detect such a 
difference. On the other hand, the incidence of the other two 
individual efﬁ  cacy end-points (ie, reinfarction and recurrent 
ischemia/angina) was favorably inﬂ  uenced by enoxaparin. 
As compared to placebo, treatment with enoxaparin was 
associated with a reduced occurrence of combined angina 
and reinfarction (Glick et al 1996; Simoons et al 2002). In 
comparison with UFH, the effect of enoxaparin on reinfarc-
tion/recurrent ischemia was a little less concordant, although 
a trend towards a lower occurrence was consistently 
observed (ASSENT 2001; Antman et al 2002; Baird et al 
2002; Wallentin et al 2003). Several reasons should be taken Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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into account when trying to explain such a ﬁ  nding. First, 
the deﬁ  nitions of these two events were highly variable in 
the various studies, ranging from recurrence of chest pain 
associated or not with ECG changes to chest pain with ECG 
changes determining re-hospitalization or performance of 
coronary angiography for recurrent angina/ischemia, and 
from recurrence of chest pain associated with ECG changes 
and (not quantiﬁ  ed) increase in CK and AST to recurrence of 
chest pain at rest associated with ST-segment elevation and 
further increase (sometimes not speciﬁ  ed, some other time 
deﬁ  ned as twice the upper normal limit or three times or ﬁ  ve 
times the upper normal limit in case it was detected follow-
ing coronary angioplasty or coronary artery bypass grafting, 
respectively) in either total CK or CK-MB isoenzyme or 
troponins for reinfarction. In addition, in the ASSENT-3 
study (ASSENT 2001), there was no central adjudication 
for the end-points of reinfarction and refractory ischemia, 
which were therefore conﬁ  rmed by the individual investiga-
tors (although in accordance with pre-speciﬁ  ed deﬁ  nitions). 
Second, the different treatment regimens with thrombolytic 
agents and heparins (Table 1) may also have played an 
important role on the discordant effects observed on recur-
rent ischemia/angina and reinfarction rates. For example, 
the superior efﬁ  cacy of enoxaparin compared to UFH on 
in-hospital refractory ischemia/reinfarction observed in 
both ASSENT-3 (ASSENT 2001) and ASSENT-3 Plus 
(Wallentin et al 2003) studies, and on the reinfarction rate at 
30 days in the ENTIRE-TIMI 23 study (Antman et al 2002), 
may well be ascribed to the longer duration of enoxaparin 
treatment, rather than to a real difference in the efﬁ  cacy of 
the two drugs. Indeed, in the study by Baird et al. (Baird 
et al 2002), where the duration of enoxaparin and UFH 
was identical, no signiﬁ  cant difference on reinfarction and 
recurrent angina rates was observed.
The safety proﬁ  le of enoxaparin, in association with aspi-
rin and thrombolysis in STEMI, is characterized in general by 
an increased occurrence of both minor and major bleedings 
compared to placebo (Simoons et al 2002) and substantially 
unchanged compared to UFH (Ross et al 2001; ASSENT 
2001; Antman et al 2002; Wallentin et al 2003). Regarding 
major hemorrhages, which however, were variably deﬁ  ned in 
the various studies (fatal, intracranial, intraperitoneal, intra-
ocular, requiring transfusion or surgical operation), no sig-
niﬁ  cant difference in the occurrence of intracranial bleeding 
was observed with enoxaparin as compared not only to UFH 
(Ross et al 2001; ASSENT 2001; Antman et al 2002; Baird 
et al 2002), but also to placebo (Simoons et al 2002), with 
the only exception of the ASSENT-3 Plus study (Wallentin 
et al 2003). In this study the administration of thrombolysis 
and enoxaparin in a pre-hospital setting was indeed associated 
with a twice higher occurrence of intracranial hemorrhage 
compared to UFH, although only in patients aged more than 
75 years (2% vs 1%; p = 0.05) (Table 2).
The ExTRACT -TIMI 25 Study
In this multi-center, double-blind, randomized trial, over 
20,000 patients receiving either a ﬁ  brin- or non ﬁ  brin-speciﬁ  c 
thrombolytic and aspirin, were randomized to enoxaparin 
Table 5 Pooled analysis of the results and relative risk (RR) of in-hospital/7 days and 30-day major bleedings in the open-label studies
  In-hospital/7-day major  Risk ratio  30-day major  Risk ratio
 bleedings*  (95%  conﬁ  dence intervals)  bleedings*  (95% conﬁ  dence intervals)
  Enoxaparin  UFH   Enoxaparin UFH
Ross et al  7/196  6/197  1.18 (0.39–3.57)  –  –  –
(2001) (HART-II)
ASSENT-3 80/2040  106/2038  1.38  (1.02–1.86)  –  –  –
(2001)
Antman et al (2002)  –  –  –  16/324  6/159  1.33 (0.51–3.45)
(ENTIRE-TIMI 23)
Wallentin et al (2003)  33/817  23/821  1.46 (0.85–2.51)  –  –  –
(ASSENT-3 PLUS)
Tatu-Chitoiu et al  –  –  –  0/165  2/264  (not applicable)
(2004) (ASENOX)
Total  120/3053  135/3056  0.86 (0.69–1.14)  16/489  8/423  1.76 (0.74–4.14)
* evaluated in the treated population.Vascular Health and Risk Management 2006:2(4) 465–475
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those in men. In addition, pathology and pathophysiology of the disease present significant
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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30 mg as an intravenous bolus followed by 1 mg/kg twice 
daily subcutaneously for up to 8 days, or intravenous bolus 
of UFH 60 IU/kg followed by infusion of 12 IU/kg/h for 48 
hours (Antman et al 2006). The primary end-point was the 
composite of death or reinfarction at 30 days, whereas sec-
ondary end points were the composite of death and reinfarc-
tion/recurrent ischemia and the composite of death, recurrent 
reinfarction and disabling stroke at 30 days. Enoxaparin was 
signiﬁ  cantly more effective than UFH on both in-hospital 
(7% vs 9%; p < 0.001) and 30-day (10% vs 12%; p < 0.001) 
primary end points (Figures 1 and 2). In both cases, this result 
was mainly driven by the signiﬁ  cant decrease in reinfarction, 
since mortality was not substantially affected (Figures 1 and 
2). Major bleedings were signiﬁ  cantly more frequent with 
enoxaparin at both 8 and 30 days, although the occurrence 
of intracranial hemorrhage was comparable (Figures 1 and 
2). However, the net clinical beneﬁ  t at 30 days, deﬁ  ned as 
the combined occurrence of death, reinfarction and either 
nonfatal disabling stroke, major bleeding or intracranial hem-
orrhage, was signiﬁ  cantly higher with enoxaparin, which was 
associated with a signiﬁ  cant 14 to 18% relative risk reduction 
of these events compared to UFH (Antman et al 2006).
Because of its design and size, the ExTRACT-TIMI 25 
study (Antman et al 2006) should be considered conclusive 
about the superior efﬁ  cacy of enoxaparin in comparison to 
UFH for the treatment of patients receiving thrombolysis for 
STEMI. Again however, it cannot be determined whether this 
result is to be ascribed to a true superior antithrombotic effect 
of enoxaparin or instead to the longer duration of treatment 
(7 days vs 48 hours). Prolonged treatment with enoxaparin, 
which can be conveniently given subcutaneously without 
need for laboratory monitoring, is likely to effectively con-
tribute to a more sustained antithrombotic effect, and should 
therefore strongly considered in these patients.
The higher occurrence of major bleedings may also well 
be ascribed to the longer duration of treatment, rather than to a 
superior dangerousness of enoxaparin (Figures 1 and 2). Since 
however, the most dreadful and disabling hemorrhagic complica-
tion, represented by intracranial bleeding, did not signiﬁ  cantly 
differ in the two groups, the safety proﬁ  le of enoxaparin should 
be considered satisfactory (Figures 1 and 2). It is of note how-
ever that among patients having a major bleeding episode, the 
30-day mortality rate was signiﬁ  cantly higher in those receiving 
enoxaparin rather than UFH (0.8% vs 0.4%; p < 0.001), being 
hemorrhage the primary cause of death in both groups (70% 
vs 77%, respectively) (Antman et al 2006). Although a clear 
explanation for such a ﬁ  nding is not apparent, the only partial 
response to protamine, as well as a possible delay in the recog-
Figure 1 Efﬁ  cacy and safety outcomes at 8 days in the ExTRACT-TIMI 25 study.
Abbreviations: UFH, unfractionated heparin; ICH, intracranial hemorrhage; RR, relative risk; NS, nonsigniﬁ  cant.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Enoxaparin and STEMI
nition of an hemorrhagic complication (due to the lack of tight 
monitoring which may allow prompt correction of the intensity 
of anticoagulation when intravenous UFH is used), may account 
for the apparent increased fatality rate of hemorrhagic events 
with enoxaparin administration.
Conclusions
The administration of enoxaparin, as a conjunct to thromboly-
sis for STEMI, is superior to both placebo and UFH, in terms 
of in-hospital and 30-day incidence of reinfarction/recurrent 
ischemia, and angiographic end-points, such as patency and 
reocclusion rates of the IRA. Provided that patients aged 
older than 75 years are excluded, especially when throm-
bolysis is performed in a pre-hospital setting, also the risk 
of hemorrhage associated with enoxaparin administration 
is probably favourable as well. In addition, the easiness of 
subcutaneous administration and the lack of need for aPTT 
monitoring greatly increase its convenience, allowing also 
prolongation of treatment, without hampering early mobiliza-
tion and rehabilitation of patients, while permitting extended 
antithrombotic treatment.
While waiting the current practice guidelines for the 
management of patients with STEMI (Van de Werf et al 
2003; Antman et al 2004) to be updated in accordance with 
these new acquisitions, the administration of enoxaparin as 
an intravenous 30 mg bolus followed by twice daily 1 mg/kg 
subcutaneous administration for about 1 week should be 
considered for patients receiving thrombolysis for STEMI. 
As appearing from a recent meta-analysis of all randomized 
trials comparing various low-molecular-weight heparins 
to both placebo and UFH in association to thrombolysis 
for STEMI (Eikelboom et al 2005), the beneﬁ  cial effect 
observed with enoxaparin is likely a property of the class of 
low-molecular-weight heparins, which therefore may prob-
ably be indifferently used.
Note
Dr. Rubboli reports having received lecture fees from Sanoﬁ  -
Aventis, and Dr. Di Pasquale reports having received lecture 
fees from and having served on paid advisory board for 
Sanoﬁ  -Aventis. Dr. Capecchi discloses no potential conﬂ  ict 
of interest.
Figure 2 Efﬁ  cacy and safety outcomes at 30 days in the ExTRACT-TIMI 25 study.
Abbreviations: UFH, unfractionated heparin; ICH, intracranial hemorrhage; RR, relative risk; NS, nonsigniﬁ  cant.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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